Leukemia, Myeloid, Chronic-phase Clinical Trial
Official title:
Phase I Study of BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
The purpose of this clinical research study is to understand the safety and efficacy of BMS-354825 in patients with chronic, accelerated, or blast phase chronic myelogenous leukemia (CML) or Philadelphia positive acute lymphoblastic leukemia (ALL) who are resistant to or intolerant of imatinib mesylate (Gleevec).
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01725204 -
Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia
|
Phase 2 | |
Completed |
NCT01856283 -
Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells
|
Phase 2 | |
Completed |
NCT00048672 -
Therapy of Early Chronic Phase CML With Gleevec
|
Phase 2 | |
Recruiting |
NCT02767063 -
Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)
|
Phase 1/Phase 2 | |
Terminated |
NCT01827930 -
Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response
|
Phase 3 | |
Terminated |
NCT01488253 -
Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants
|
Phase 2 | |
Withdrawn |
NCT01650467 -
Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms
|
N/A | |
Completed |
NCT02888964 -
Pioglityazone and Imatinib for CML Patients
|
Phase 2 | |
Active, not recruiting |
NCT03239886 -
Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log
|
N/A | |
Terminated |
NCT03807479 -
Study in Patients With Chronic Leukemia
|
Phase 2 |